Dr. Lum is a Professor of Oncology at the University of Virginia School of Medicine, Director of Cellular Therapy, and Scientific Director of BMT. In the past 20 years, he conducted the first experimental trials using immunotherapy in combination with SCT for leukemia, lymphoma, multiple myeloma, and breast cancer using activated T cells. He more recently focused on using Bispecific antibody Armed T cells (BATs) to treat women with early- and late-stage breast cancer and patients with prostate, pancreatic, and colon cancer. His current efforts focus on using targeted T cells to improve clinical and immunologic responses in patients with breast cancer and pancreatic cancer.